Fundies. English
Segment disclosures
Company overviewDANAHER CORPORATION
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
169 dimension combinations 777 retained observations 14 reported periods Partial retained history
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring · Biotechnology
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 1001000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1275000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring · Biotechnology Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 155000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 869000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 208000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 519000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 156000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 311000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 155000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1001000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 231000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 681000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 235000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 450000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 215000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1275000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 274000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 978000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring · Diagnostics
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 252000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 725000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 247000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 473000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 226000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1068000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 236000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 726000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 257000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 490000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 233000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1152000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 268000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 805000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring · Diagnostics Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 231000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 1082000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 226000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1068000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1152000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring · Life Sciences
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 576000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1683000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 563000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1107000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 544000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2440000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 554000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1669000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 562000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1115000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 553000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2781000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 644000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 2006000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring · Life Sciences Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 534000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 2490000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 544000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2440000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2781000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Biotechnology
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 5758000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 5897000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Biotechnology Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 1642000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 6424000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1590000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 4741000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1694000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 3151000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1457000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 5758000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 1422000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 4209000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1478000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 2787000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1309000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 5897000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1390000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 4435000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Diagnostics
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 2211000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 6496000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 2062000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 4285000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 2223000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 8719000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 2127000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 6424000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 2003000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 4297000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 2294000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 8425000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1986000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 6056000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Diagnostics Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 2186000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 8859000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 2223000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 8719000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 8425000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Environmental Applied Solutions
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 742000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1466000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Life Sciences
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 1216000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 3566000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1214000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 2350000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1136000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 4889000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 1228000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 3628000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1208000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 2400000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1192000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4360000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1062000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 3205000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring · Life Sciences Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 1203000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 4844000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1136000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 4889000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4360000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · High Growth Markets · Biotechnology Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 490000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 1976000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 498000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1385000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 448000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 887000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 439000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1891000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 485000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1328000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 458000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 843000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1982000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · High Growth Markets · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 721000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 2107000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 746000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1386000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 737000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 2165000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 743000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1428000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · High Growth Markets · Diagnostics Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 635000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 2922000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 640000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2933000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 3096000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · High Growth Markets · Life Sciences
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 542000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1503000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 503000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 961000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 501000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1463000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 495000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 962000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · High Growth Markets · Life Sciences Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 499000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 2124000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 458000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2046000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2113000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Other Developed Markets · Biotechnology Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 57000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 341000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 89000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 235000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 82000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 146000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 64000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 335000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 78000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 238000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 81000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 160000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 329000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Other Developed Markets · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 97000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 282000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 94000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 185000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 101000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 295000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 95000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 194000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · Other Developed Markets · Diagnostics Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 86000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 393000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 91000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 408000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 431000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Other Developed Markets · Life Sciences
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 130000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 371000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 118000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 241000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 120000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 361000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 116000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 241000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · Other Developed Markets · Life Sciences Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 141000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 518000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 123000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 510000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 510000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Western Europe · Biotechnology Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 726000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 2558000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 587000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1861000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 708000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1274000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 566000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2296000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 587000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1700000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 567000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1113000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2407000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Western Europe · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 417000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1222000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 405000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 805000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 368000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1154000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 380000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 786000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · Western Europe · Diagnostics Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 431000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 1706000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 400000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1587000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1542000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Western Europe · Life Sciences
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 392000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1164000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 394000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 772000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 365000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1111000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 374000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 746000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · Western Europe · Life Sciences Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 408000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 1674000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 378000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1574000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1519000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · North America · Biotechnology Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 524000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 2418000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 624000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1779000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 612000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1155000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 543000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2237000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 503000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1624000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 607000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1121000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2454000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · North America · Diagnostics
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 1228000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 3610000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1064000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 2382000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 1157000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 3536000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1042000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 2379000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · North America · Diagnostics Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 1265000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 4920000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1318000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 4859000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4508000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · North America · Environmental Applied Solutions
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 577000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1149000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · North America · Life Sciences
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 728000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 2211000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 762000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1483000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 796000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 2362000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 785000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1566000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
Operating Segments · North America · Life Sciences Segment
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-27 | 689000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 3018000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 721000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 3199000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2999000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Biotechnology
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 6759000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 7172000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Operating Segments · Biotechnology Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 1920000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 3717000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-27 | 1797000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 7293000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1798000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 5260000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1850000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 3462000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1612000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 6759000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 1653000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 4890000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1713000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 3237000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1524000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 7172000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1664000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 5413000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1885000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 3749000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Biotechnology Segment · Revenuefrom Contractwith Customer Measurement Recurring
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 1534000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 3045000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Biotechnology Segment · Otherdevelopedmarkets
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 72000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 151000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Biotechnology Segment · Western Europe
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 684000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1331000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Biotechnology Segment · North America
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 611000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1229000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Diagnostics
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 2463000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 7221000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 2309000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 4758000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 2449000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 9787000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 2363000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 7150000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 2260000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 4787000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 2527000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 9577000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 2254000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 6861000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 2231000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 4607000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Diagnostics · Revenuefrom Contractwith Customer Measurement Nonrecurring
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 1152000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Operating Segments · Diagnostics · Revenuefrom Contractwith Customer Measurement Recurring
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 1958000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 4070000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Diagnostics · Highgrowthmarkets
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 3096000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Operating Segments · Diagnostics · Otherdevelopedmarkets
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 431000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 100000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 217000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Diagnostics · Western Europe
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 365000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 785000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Diagnostics · North America
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 982000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 2106000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Diagnostics Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 2466000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 4883000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-27 | 2417000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 9941000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 2309000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 4758000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 2449000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 9787000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 9577000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Operating Segments · Environmental Applied Solutions
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 1245000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 2463000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Environmental Applied Solutions · Otherdevelopedmarkets
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 31000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 60000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Environmental Applied Solutions · Western Europe
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 284000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 561000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Life Sciences
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-06-28 – 2025-09-26 | 1792000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 5249000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1777000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 3457000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1680000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 7329000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 1782000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 5297000000 | USD | 2025-10-20 · 21:56:13.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1770000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 3515000000 | USD | 2025-07-21 · 22:39:11.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1745000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 7141000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1706000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 5211000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1796000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 3505000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Life Sciences · Revenuefrom Contractwith Customer Measurement Recurring
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 1104000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 2143000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Life Sciences · Otherdevelopedmarkets
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 124000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 252000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Life Sciences · Western Europe
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 375000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 739000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Life Sciences · North America
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 757000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1465000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Operating Segments · Life Sciences Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 1879000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 3616000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-27 | 1737000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 7334000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1777000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 3457000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-28 | 1680000000 | USD | 2026-04-20 · 21:40:21.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 7329000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 7141000000 | USD | 2026-02-24 · 21:36:41.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments · Biotechnology Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 351000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 704000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments · Diagnostics
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 268000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 805000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 273000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 537000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments · Environmental Applied Solutions
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 503000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 997000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments · Life Sciences
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 644000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 2006000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 692000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1362000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Biotechnology Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 198000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 353000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 156000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 311000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 235000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 450000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 215000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 351000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 704000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Diagnostics · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 233000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Diagnostics Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 256000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 487000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 247000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 473000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Life Sciences · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 562000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1115000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 692000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1362000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Nonrecurring · Life Sciences Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 611000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1145000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 563000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1107000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Operating Segments · Diagnostics
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 8425000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Biotechnology · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 5897000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Biotechnology Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 1722000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 3364000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1694000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 3151000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1478000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 2787000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1309000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1534000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 3045000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Diagnostics · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 2294000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Diagnostics Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 2210000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 4396000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 2062000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 4285000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Life Sciences · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 1208000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 2400000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4360000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1104000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 2143000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Revenuefrom Contractwith Customer Measurement Recurring · Life Sciences Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 1268000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 2471000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1214000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 2350000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
High Growth Markets · Operating Segments · Biotechnology
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 1891000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1982000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Highgrowthmarkets · Operating Segments · Biotechnology Segment
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-06-29 – 2024-09-27 | 485000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1328000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 485000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1523000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 518000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1038000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
High Growth Markets · Operating Segments · Biotechnology Segment
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 439000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 385000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
Highgrowthmarkets · Operating Segments · Diagnostics
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-06-29 – 2024-09-27 | 737000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 2165000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 761000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 2260000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 784000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1499000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
High Growth Markets · Operating Segments · Diagnostics
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 640000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2933000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 685000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 3096000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Highgrowthmarkets · Operating Segments · Environmental Applied Solutions
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-06-30 | 353000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 693000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
Highgrowthmarkets · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-06-29 – 2024-09-27 | 501000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1463000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 505000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1554000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 540000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1049000000 | USD | 2023-07-24 · 21:46:33.000Z | Open filing evidence |
High Growth Markets · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 458000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 2046000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 467000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2113000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Highgrowthmarkets · Biotechnology Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 458000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 843000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 385000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 518000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1038000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
High Growth Markets · Biotechnology Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 574000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1064000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 448000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 887000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
High Growth Markets · Diagnostics Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 811000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1446000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 746000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1386000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Highgrowthmarkets · Life Sciences · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 495000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 962000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 540000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1049000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
High Growth Markets · Life Sciences Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 573000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1072000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 503000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 961000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Other Developed Markets · Operating Segments · Biotechnology
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 335000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 329000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Otherdevelopedmarkets · Operating Segments · Biotechnology Segment
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-06-29 – 2024-09-27 | 78000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 238000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 78000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 229000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Other Developed Markets · Operating Segments · Biotechnology Segment
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 64000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 79000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
Otherdevelopedmarkets · Operating Segments · Diagnostics
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-06-29 – 2024-09-27 | 101000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 295000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 105000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 322000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Other Developed Markets · Operating Segments · Diagnostics
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 91000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 408000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 99000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 431000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Otherdevelopedmarkets · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-06-29 – 2024-09-27 | 120000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 361000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 117000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 369000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Other Developed Markets · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 123000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 510000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 125000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 510000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Other Developed Markets · Biotechnology Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 74000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 131000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 82000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 146000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Other Developed Markets · Diagnostics Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 93000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 179000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 94000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 185000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Other Developed Markets · Life Sciences Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 126000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 267000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 118000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 241000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Western Europe · Operating Segments · Biotechnology
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 2296000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2407000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
Western Europe · Operating Segments · Biotechnology Segment
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 566000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 587000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1700000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 546000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 508000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1839000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Western Europe · Operating Segments · Diagnostics
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 400000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1587000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 368000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1154000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 406000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1542000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 334000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1119000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Western Europe · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 378000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1574000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 365000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1111000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 372000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1519000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 356000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1095000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
Western Europe · Biotechnology Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 689000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1415000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 708000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1274000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 546000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Western Europe · Diagnostics · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 406000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Western Europe · Diagnostics Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 430000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 861000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 405000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 805000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Western Europe · Life Sciences Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=dhr:WesternEuropeMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 421000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 829000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 394000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 772000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
North America · Operating Segments · Biotechnology
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 2237000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2454000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
North America · Operating Segments · Biotechnology Segment
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 543000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 503000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 1624000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 514000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 593000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1822000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
North America · Operating Segments · Diagnostics
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 1318000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 4859000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 1157000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 3536000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1337000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4508000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1054000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 3160000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
North America · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-28 | 721000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 3199000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2024-06-29 – 2024-09-27 | 796000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-09-27 | 2362000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 781000000 | USD | 2025-04-22 · 10:03:03.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2999000000 | USD | 2025-02-20 · 21:18:06.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 728000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 2193000000 | USD | 2024-10-21 · 21:38:16.000Z | Open filing evidence |
North America · Biotechnology Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 583000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1107000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 612000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1155000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 514000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 593000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1822000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
North America · Diagnostics · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 1337000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
North America · Diagnostics Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 1132000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 2397000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 1064000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 2382000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
North America · Environmental Applied Solutions · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 599000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1748000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
North America · Life Sciences · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2999000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
North America · Life Sciences Segment · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-03-28 – 2026-06-26 | 759000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2026-01-01 – 2026-06-26 | 1448000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-03-29 – 2025-06-27 | 762000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
| 2025-01-01 – 2025-06-27 | 1483000000 | USD | 2026-07-20 · 21:48:38.000Z | Open filing evidence |
Biotechnology · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 7172000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Biotechnology · Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 1275000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Biotechnology · Operating Segments · Highgrowthmarkets
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 1982000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Biotechnology · Operating Segments · Otherdevelopedmarkets
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 329000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Biotechnology · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2407000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Biotechnology · North America · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologyMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2454000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Biotechnology Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 1807000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 5524000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1798000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 5260000000 | USD | 20261021 | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 1713000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 3237000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1524000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 1664000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 5413000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1885000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 3749000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Biotechnology Segment · Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 1390000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 4435000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Biotechnology Segment · Operating Segments · Otherdevelopedmarkets
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 79000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Biotechnology Segment · Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 223000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 576000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 208000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 519000000 | USD | 20261021 | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 274000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 978000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Biotechnology Segment · Revenuefrom Contractwith Customer Measurement Recurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 1584000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 4948000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1590000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 4741000000 | USD | 20261021 | Open filing evidence |
Biotechnology Segment · Highgrowthmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 485000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1523000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Biotechnology Segment · High Growth Markets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 594000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 1658000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 498000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1385000000 | USD | 20261021 | Open filing evidence |
Biotechnology Segment · Otherdevelopedmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 81000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 160000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 78000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 229000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 72000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 151000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Biotechnology Segment · Other Developed Markets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 58000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 189000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 89000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 235000000 | USD | 20261021 | Open filing evidence |
Biotechnology Segment · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 605000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 2020000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 587000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1861000000 | USD | 20261021 | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 567000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1113000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-07-01 – 2023-09-29 | 508000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1839000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 684000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1331000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Biotechnology Segment · North America · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:BiotechnologySegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 550000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 1657000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 624000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1779000000 | USD | 20261021 | Open filing evidence |
| 2024-03-30 – 2024-06-28 | 607000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1121000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 611000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 1229000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 2260000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 4787000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 2527000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 2231000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 4607000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics · Operating Segments · Otherdevelopedmarkets
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 99000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Diagnostics · Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 257000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 490000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics · Revenuefrom Contractwith Customer Measurement Recurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 2003000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 4297000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics · Highgrowthmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 743000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1428000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 685000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Diagnostics · Otherdevelopedmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 95000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 194000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 380000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 786000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics · North America · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 1042000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 2379000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Diagnostics Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 2882000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 7765000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 2463000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 7221000000 | USD | 20261021 | Open filing evidence |
Diagnostics Segment · Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 349000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 836000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 252000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 725000000 | USD | 20261021 | Open filing evidence |
Diagnostics Segment · Revenuefrom Contractwith Customer Measurement Recurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 2533000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 6929000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 2211000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 6496000000 | USD | 20261021 | Open filing evidence |
Diagnostics Segment · High Growth Markets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 861000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 2307000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 721000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 2107000000 | USD | 20261021 | Open filing evidence |
Diagnostics Segment · Other Developed Markets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 108000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 287000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 97000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 282000000 | USD | 20261021 | Open filing evidence |
Diagnostics Segment · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 474000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 1335000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 417000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1222000000 | USD | 20261021 | Open filing evidence |
Diagnostics Segment · North America · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:DiagnosticsSegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 1439000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 3836000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1228000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 3610000000 | USD | 20261021 | Open filing evidence |
Environmental Applied Solutions · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 1249000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 3712000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Environmental Applied Solutions · Operating Segments · Revenuefrom Contractwith Customer Measurement Recurring
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 744000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 2210000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Environmental Applied Solutions · Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 505000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1502000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Environmental Applied Solutions · Highgrowthmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 351000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 1044000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Environmental Applied Solutions · Otherdevelopedmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 30000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 90000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Environmental Applied Solutions · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:EnvironmentalAppliedSolutionsMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-29 | 269000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
| 2023-01-01 – 2023-09-29 | 830000000 | USD | 2023-10-23 · 21:43:27.000Z | Open filing evidence |
Life Sciences · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 1770000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 3515000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 1745000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 7141000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Life Sciences · Operating Segments · Revenuefrom Contractwith Customer Measurement Nonrecurring
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2781000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Life Sciences · Operating Segments · Highgrowthmarkets
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2113000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Life Sciences · Operating Segments · Otherdevelopedmarkets
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 125000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 510000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Life Sciences · Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 553000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Life Sciences · Revenuefrom Contractwith Customer Measurement Recurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 1192000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Life Sciences · Highgrowthmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=dhr:HighgrowthmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-29 | 467000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Life Sciences · Otherdevelopedmarkets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=dhr:OtherdevelopedmarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 116000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 241000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
Life Sciences · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 374000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 746000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 372000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1519000000 | USD | 2024-02-21 · 21:38:09.000Z | Open filing evidence |
Life Sciences · North America · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-03-30 – 2024-06-28 | 785000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-06-28 | 1566000000 | USD | 2024-07-22 · 21:41:46.000Z | Open filing evidence |
| 2024-01-01 – 2024-03-29 | 781000000 | USD | 2024-04-22 · 21:53:08.000Z | Open filing evidence |
Life Sciences Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 1865000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 5481000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1792000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 5249000000 | USD | 20261021 | Open filing evidence |
Life Sciences Segment · Revenuefrom Contractwith Customer Measurement Nonrecurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 583000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 1728000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 576000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1683000000 | USD | 20261021 | Open filing evidence |
Life Sciences Segment · Revenuefrom Contractwith Customer Measurement Recurring · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:ProductOrServiceAxis=dhr:RevenuefromContractwithCustomerMeasurementRecurringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 1282000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 3753000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 1216000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 3566000000 | USD | 20261021 | Open filing evidence |
Life Sciences Segment · High Growth Markets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:StatementGeographicalAxis=dhr:HighGrowthMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 571000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 1643000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 542000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1503000000 | USD | 20261021 | Open filing evidence |
Life Sciences Segment · Other Developed Markets · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:StatementGeographicalAxis=dhr:OtherDevelopedMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 132000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 399000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 130000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 371000000 | USD | 20261021 | Open filing evidence |
Life Sciences Segment · Western Europe · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:StatementGeographicalAxis=dhr:WesternEuropeMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 411000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 1240000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 392000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 1164000000 | USD | 20261021 | Open filing evidence |
Life Sciences Segment · North America · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=dhr:LifeSciencesSegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-06-27 – 2026-09-25 | 751000000 | USD | 20261021 | Open filing evidence |
| 2026-01-01 – 2026-09-25 | 2199000000 | USD | 20261021 | Open filing evidence |
| 2025-06-28 – 2025-09-26 | 728000000 | USD | 20261021 | Open filing evidence |
| 2025-01-01 – 2025-09-26 | 2211000000 | USD | 20261021 | Open filing evidence |